Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Development of an improved vaccine for anthrax
Stephen H. Leppla, John B. Robbins, Rachel Schneerson, Joseph Shiloach
Stephen H. Leppla, John B. Robbins, Rachel Schneerson, Joseph Shiloach
View: Text | PDF
Perspective

Development of an improved vaccine for anthrax

  • Text
  • PDF
Abstract

Perspective

Authors

Stephen H. Leppla, John B. Robbins, Rachel Schneerson, Joseph Shiloach

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
PA regions targeted by neutralizing antibodies. PA monomer (left) is cle...
PA regions targeted by neutralizing antibodies. PA monomer (left) is cleaved by cellular furin, releasing domain 1a (amino acids 1–167, colored gray), and allowing the remaining domains to assemble into a heptameric channel (right). Domains remaining in the heptamer are 1b (yellow), 2 (red), 3 (blue), and 4 (green). Indicated in black within domain 4 is the “small loop,” amino acids 680–692, which is involved in binding to the PA receptor. The neutralizing mouse mAb 14B7 reacts with this region, preventing PA binding to the receptor. In the heptamer, the “top” of domain 1a contains a surface on which LF and EF bind to initiate internalization. Neutralizing mouse mAb 1G3 binds to this same surface, competing with EF and LF, and thereby blocking their action. This figure was created with Protein Explorer (35), available at http://www.umass.edu/microbio/chime/explorer, using existing PAmonomer and heptamer structure files contained in an Atlas of Macromolecules available at http://www.umass.edu/microbio/chime/explorer/index2.htm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts